Advertisement

Sarcopenia and Myopathies in the Elderly

  • Kenneth S. O’RourkeEmail author
Chapter

Abstract

Muscle disease symptoms and myopathies are not uncommon in the elderly population. Inflammatory and noninflammatory myopathies lead primarily to proximal extremity or axial weakness and are superimposed upon the intrinsic age-related changes that occur in muscle mass, strength, and function (sarcopenia). This chapter surveys the more common myopathies in the elderly population based upon a review of the process of sarcopenia, and how these age-related changes in muscle structure and function affect the results of the standard assessments of muscle disease in the elderly individual.

Keywords

Muscle Myopathy Myositis Sarcopenia 

References

  1. 1.
    Rosenberg IH. Sarcopenia: origins and relevance. J Nutr. 1997;127:990S.PubMedGoogle Scholar
  2. 2.
    Cruz-Jentoft AJ, Landi F, Topinkova E, Michel J-P (2010) Understanding sarcopenia as a geriatric syndrome. Curr Opin Clin Nutr Metab Care 13, epub DOI:  10.1097/MC0.0b013e328333c1c1.
  3. 3.
    Doherty TJ. Aging and sarcopenia. J Appl Physiol. 2003;95:1717–27.PubMedGoogle Scholar
  4. 4.
    Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci. 2002;57:M772–7.PubMedGoogle Scholar
  5. 5.
    Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R. Skeletal muscle cutpoints associated with elevated physical ­disability risk in older men and women. Am J Epidemiol. 2004;159:413–21.PubMedGoogle Scholar
  6. 6.
    Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147:755–63.PubMedGoogle Scholar
  7. 7.
    van Kan GA, Andre E, Bischoff-Ferrari HA, Boirie Y, Onder G, Pahor M, et al. Carla task force on sarcopenia: propositions for clinical trials. J Nutr Health Aging. 2009;13:700–7.Google Scholar
  8. 8.
    Campbell WW. Synergistic use of higher-protein diets or nutritional supplements with resistance training to counter sarcopenia. Nutr Rev. 2007;65:416–22.PubMedGoogle Scholar
  9. 9.
    Thomas DR. Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. Clin Nutr. 2007;26:389–99.PubMedGoogle Scholar
  10. 10.
    Janssen I. Influence of sarcopenia on the development of physical disability: the Cardiovascular Health Study. J Am Geriatr Soc. 2006;54:56–62.PubMedGoogle Scholar
  11. 11.
    Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geraitr Soc. 2007;55:780–91.Google Scholar
  12. 12.
    Kanapuru B, Ershler WB. Inflammation, coagulation, and the pathway to fraility. Am J Med. 2009;122:605–13.PubMedGoogle Scholar
  13. 13.
    Lexell J, Taylor CC, Sjöström M. What is the cause of aging atrophy? Total number, size, and proportion of different fiber types studied in whole vastus lateralis muscle from 15-to-83-year-old men. J Neurol Sci. 1998;84:275.Google Scholar
  14. 14.
    Evans W. Functional and metabolic consequences of sarcopenia. J Nutr. 1997;127:998S.PubMedGoogle Scholar
  15. 15.
    Schwartz RS, Buchner DM. Exercise in the elderly: physiologic and functional effects. In: Hazzard WR, Blass JP, Ettinger WH, Halter JB, Ouslander JG, editors. Principles of geriatric medicine and gerontology. 4th ed. New York: McGraw-Hill; 1999. p. 143–58.Google Scholar
  16. 16.
    Conley KE, Cress ME, Jubrias SA, et al. From muscle proteins to human performance, using magnetic resonance. J Gerontol. 1995;50A:35.Google Scholar
  17. 17.
    Lexell J. Human aging, muscle mass, and fiber type composition. J Gerontol. 1995;50A:11.Google Scholar
  18. 18.
    Lexell J, Downham D. What is the effect of ageing on type 2 muscle fibers? J Neurol Sci. 1992;107:250.PubMedGoogle Scholar
  19. 19.
    Bemben MG. Age-related physiological alterations to muscles and joints and potential exercise interventions for their improvement. J Okla State Med Assoc. 1999;92:13.PubMedGoogle Scholar
  20. 20.
    Ryall JG, Schertzer JD. Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness. Biogerontology. 2008;9:213–28.PubMedGoogle Scholar
  21. 21.
    Schultz AB. Muscle function and mobility biomechanics in the elderly: an overview of some recent research. J Gerontol. 1995;50A:60.Google Scholar
  22. 22.
    Yu F, Hedstrom M, Cristea A, Dalen N, Larsson L. Effects of ageing and gender on contractile properties in human skeletal muscle and single fibers. Acta Physiol. 2007;190:229–41.Google Scholar
  23. 23.
    Lexell J. Evidence for nervous system degeneration with advancing age. J Nutr. 1997;127:1011S.PubMedGoogle Scholar
  24. 24.
    Delbono O, O’Rourke K, Ettinger W. Excitation-calcium release uncoupling in aged single human skeletal muscle fibers. J Membr Biol. 1995;148:211.PubMedGoogle Scholar
  25. 25.
    Faulkner JA, Brooks SV, Zerba E. Muscle atrophy and weakness with aging: contraction-induced injury as an underlying mechanism. J Gerontol. 1995;50A:124.Google Scholar
  26. 26.
    Degens H. Age-related changes in the microcirculation of skeletal muscle. Adv Exp Med Biol. 1998;454:343.PubMedGoogle Scholar
  27. 27.
    Nair KS. Aging muscle. Am J Clin Nutr. 2005;81:953–63.PubMedGoogle Scholar
  28. 28.
    Goldspink G. Age-related loss of skeletal muscle function; impairment of gene expression. J Musculoskelet Neuronal Interact. 2004;4:143–7.PubMedGoogle Scholar
  29. 29.
    Payette H, Roubenoff R, Jacques PF, Dinarello CA, Wilson PW, Abad LW, et al. Insulin-like growth factor-1 and interleukin 6 predict sarcopenia in very old community-living men and women: the Framingham Heart Study. J Am Geriatr Soc. 2003;51:1237–43.PubMedGoogle Scholar
  30. 30.
    Hiona A, Leeuwenburgh C. The role of mitochondrial DNA ­mutations in aging and sarcopenia: implications for the mitochondrial vicious cycle theory of aging. Exp Gerontol. 2008;43:24–33.PubMedGoogle Scholar
  31. 31.
    Boirie Y. Physiopathological mechanism of sarcopenia. J Nutr Health Aging. 2009;13:717–23.PubMedGoogle Scholar
  32. 32.
    Edstrom E, Altun M, Bergman E, Johnson H, Kullberg S, Ramirez-Leon V, et al. Factors contributing to neuromuscular impairment and sarcopenia during aging. Physiol Behav. 2007;92:129–35.PubMedGoogle Scholar
  33. 33.
    Delbono O. Neural control of aging skeletal muscle. Aging Cell. 2003;2:21–9.PubMedGoogle Scholar
  34. 34.
    Ceglia L. Vitamin D and its role in skeletal muscle. Curr Opin Clin Nutr Metab Care. 2009;12:628–33.PubMedGoogle Scholar
  35. 35.
    Combaret L, Dardevet D, Bechet D, Taillander D, Mosoni L, Attaix. Skeletal muscle proteolysis in aging. Curr Opin Clin Nutr Metab Care. 2009;12:37–41.Google Scholar
  36. 36.
    Carlson ME, Suetta C, Conboy MJ, Aagaard P, Mackey A, Kjaer M, et al. Molecular aging and rejuvenation of human muscle stem cells. EMBP Mol Med. 2009;1:381–91.Google Scholar
  37. 37.
    Luff AR. Age-associated changes in the innervation of muscle fibers and changes in the mechanical properties of motor units. Ann NY Acad Sci. 1998;854:92.PubMedGoogle Scholar
  38. 38.
    Venning G. Recent developments in vitamin D deficiency and muscle weakness among elderly people. BMJ. 2005;330(7490):524–6.PubMedGoogle Scholar
  39. 39.
    Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81:353–73.PubMedGoogle Scholar
  40. 40.
    US Department of Health and Human Services. Physical activity and health: a report of the Surgeon General. Atlanta: National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention; 1996.Google Scholar
  41. 41.
    U.S. Department of Health and Human Services. (last updated 16 October 2008) Physical activity guidelines for Americans. Chapter 5: Active older adults. http://health.gov/paguidelines/guidelines/chapter5.aspx. Accessed 22 June 2010.
  42. 42.
    Buchner DM. Preserving mobility in older adults. West J Med. 1997;167:258.PubMedGoogle Scholar
  43. 43.
    Anderson LC, Cutter NC. Immobility. In: Hazzard WR, Blass JP, Ettinger WH, Halter JB, Ouslander JG, editors. Principles of geriatric medicine and gerontology. 4th ed. New York: McGraw-Hill; 1999. p. 1565–75.Google Scholar
  44. 44.
    Bloomfield SA. Changes in musculoskeletal structure and function with prolonged bed rest. Med Sci Sports Exerc. 1997;29:197.PubMedGoogle Scholar
  45. 45.
    Evans WJ. Reversing sarcopenia: how weight training can build strength and vitality. Geriatrics 1996;51(May):46.Google Scholar
  46. 46.
    National Institute on Aging: Assessing Physical Performance in the Older Patient page. Available at www.grc.nia.nih.gov/branches/ledb/sppb/index.htm. Accessed 22 June 2010.
  47. 47.
    Evans WJ, Cyr-Campbell D. Nutrition, exercise, and healthy aging. J Am Diet Assoc. 1997;97:632.PubMedGoogle Scholar
  48. 48.
    Fiatarone MA, Marks RND, et al. High-intensity strength training in nonagenarians. Effects onskeletal muscle. JAMA. 1990;263:3029.PubMedGoogle Scholar
  49. 49.
    Mazzeo RS, Cavanagh P, Evans WJ, et al. ACSM position stand on exercise and physical activity for older adults. Med Sci Sports Exerc. 1998;30:992.Google Scholar
  50. 50.
    Roubenoff R. Physical activity, inflammation, and muscle loss. Nutr Rev. 2007;65:S208–12.PubMedGoogle Scholar
  51. 51.
    Rolland Y, Pillard F. Validated treatments and therapeutic perspectives regarding physical activities. J Nutr Health Aging. 2009;13:742–5.PubMedGoogle Scholar
  52. 52.
    Taaffe DR. Sarcopenia. Exercise as a treatment strategy. Aust Fam Phys. 2006;35:130–3.Google Scholar
  53. 53.
    Province MA, Hadley EC, Hornbrook MC, et al. The effects of exercise on falls in elderly patients. A preplanned meta-analysis of the FICSIT trials. JAMA. 1995;273:1341.PubMedGoogle Scholar
  54. 54.
    Bean JF, Vora A, Frontera WR. Benefits of exercise for ­community-dwelling older adults. Arch Phys Med Rehabil. 2004;85 suppl 3:S31–42.PubMedGoogle Scholar
  55. 55.
    Gaffney-Stomberg E, Insogna KL, Rodriguez NR, Kerstetter JE. Increasing dietary protein requirements in elderly people for optimal muscle and bone health. J Am Geriatr Soc. 2009;57:1073–9.PubMedGoogle Scholar
  56. 56.
    Morley JE. Sarcopenia: diagnosis and treatment. J Nutr Health Aging. 2008;12:452–6.PubMedGoogle Scholar
  57. 57.
    Kim J-S, Wilson JM, Lee S-R. Dietary implications on mechanisms of sarcopenia: roles of protein, amino acids and antioxidants. J Nutr Biochem. 2010;21:1–13.PubMedGoogle Scholar
  58. 58.
    Bischoff-Ferrari HA. Validated treatments and therapeutic perspectives regarding nutritherapy. J Nutr Health Aging. 2009;13:737–41.PubMedGoogle Scholar
  59. 59.
    Onder G, Vedova CD, Landi F. Validated treatments and therapeutics prospective regarding pharmacological products for sarcopenia. J Nutr Health Aging. 2009;13:746–56.PubMedGoogle Scholar
  60. 60.
    Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372:234–45.PubMedGoogle Scholar
  61. 61.
    Medical Research Council of the United Kingdom. Aids to the examination of the peripheral nervous system. United Kingdom: Pendragon House; 1978.Google Scholar
  62. 62.
    Wheeler J, Woodward C, Ucovich RL, et al. Rising from a chair. Influence of age and chair design. Phys Ther. 1985;65:22.PubMedGoogle Scholar
  63. 63.
    Steinhagen-Thiessen E, Hilz H. The age-dependent decrease in creatine kinase and aldolase activities in human striated muscle is not caused by an accumulation of faulty proteins. Mech Ageing Devel. 1976;5:447.Google Scholar
  64. 64.
    Tietz NW, Wekstein DR, Shuey DF, et al. A two-year longitudinal reference range study for selected enzymes in a population more than 60 years of age. J Am Geriatr Soc. 1984;32:563.PubMedGoogle Scholar
  65. 65.
    Lacomis D, Chad DA, Smith TW. Myopathy in the elderly: evaluation of the histopathologic spectrum and the accuracy of clinical diagnosis. Neurology. 1993;43:825.PubMedGoogle Scholar
  66. 66.
    Marie I, Hatron P-Y, Levesque H, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine. 1999;78:139.PubMedGoogle Scholar
  67. 67.
    Gunst JJ, Langlois MR, Delanghe JR, et al. Serum creatine kinase activity is not a reliable marker for muscle damage in conditions associated with low extracellular glutathione concentration. Clin Chem. 1998;44:939.PubMedGoogle Scholar
  68. 68.
    Buchthal F. Electromyography in the evaluation of muscle disease. Neurol Clin. 1985;3:573.PubMedGoogle Scholar
  69. 69.
    Bischoff C, Machetanz J, Conrad B. Is there an age dependent continuous increase in the duration of the motor unit action potential? Clin Neurophysiol. 1991;81:304.Google Scholar
  70. 70.
    Macdonell RAL, Shahani BT. Clinical electrophysiology in the elderly. In: Albert ML, Knoefel JE, editors. Clinical neurology of aging. 2nd ed. New York: Oxford University Press; 1994. p. 266–73.Google Scholar
  71. 71.
    Buchthal F, Pinelli P, Rosenfalk P. Action potentials in normal human muscle and their physiologic determinants. Acat Physiol Scand. 1954;32:219.Google Scholar
  72. 72.
    Feinstein B, Pattle RE, Weddell CT. Metabolic factors affecting fibrillation in denervated muscle. J Neurol Neurosurg Psychiatry. 1945;8:1.PubMedGoogle Scholar
  73. 73.
    Campellone JV, Lacomis D, Giuliani MJ, et al. Percutaneous needle muscle biopsy in the evaluation of patients with suspected inflammatory myopathy. Arthritis Rheum. 1997;40:1886.PubMedGoogle Scholar
  74. 74.
    Magistris MR, Kohler A, Pizzolato G, et al. Needle muscle biopsy in the investigation of neuromuscular disorders. Muscle Nerve. 1998;21:194.PubMedGoogle Scholar
  75. 75.
    O’Rourke KS, Blaivas M, Ike RW. Utility of needle muscle biopsy in a university rheumatology practice. J Rheumatol. 1994;21:413.PubMedGoogle Scholar
  76. 76.
    O’Rourke KS, Ike RW. Muscle biopsy. Curr Opin Rheum. 1995;7:462.Google Scholar
  77. 77.
    Flanigan KM, Lauria G, Griffin JW, et al. Age-related biology and disease of muscle and nerve. Neuro Clin North Am. 1998;16:659.Google Scholar
  78. 78.
    Rifai Z, Welle S, Kamp C, et al. Ragged red fibers in normal aging and inflammatory myopathy. Ann Neurol. 1995;37:24.PubMedGoogle Scholar
  79. 79.
    Verdijk LB, Koopman R, Schaart G, Meijer K, Savelberg HHCM, van Loon LJC. Satellite cell content is specifically reduced in type II skeletal muscle fibers in the elderly. Am J Physiol Endocrinol Metab. 2007;292:E151–7.PubMedGoogle Scholar
  80. 80.
    Yunis J, Samaha F. Inclusion body myositis. Lab Invest. 1971;25:240.PubMedGoogle Scholar
  81. 81.
    Argov Z, Tiram E, Eisenberg I, et al. Various types of hereditary inclusion body myopathies map to chrosome 9p1-q1. Ann Neurol. 1997;41:548.PubMedGoogle Scholar
  82. 82.
    Askanas V, Engel WK. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis. Curr Opin Rheum. 1998;10:530.Google Scholar
  83. 83.
    Askanas V, Engel WK. Sporadic inclusion-body myositis and hereditary inclusion body myopathies. Diseases of oxidative stress and aging? Arch Neurol. 1998;55:915.PubMedGoogle Scholar
  84. 84.
    Santorelli FM, Sciacco M, Tanji K, et al. Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patients. Ann Neurol. 1996;39:789.PubMedGoogle Scholar
  85. 85.
    Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathologic boundaries. Ann Neurol. 1996;40:581.PubMedGoogle Scholar
  86. 86.
    Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38:705.PubMedGoogle Scholar
  87. 87.
    Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med. 1991;325:1487.PubMedGoogle Scholar
  88. 88.
    Maat-Schieman MLC, Macfarlane JD, Bots GTAM, et al. Inclusion body myositis: its relative frequency in elderly people. Clin Neurol Neurosurg. 1992;94(suppl):S118.PubMedGoogle Scholar
  89. 89.
    Sivakumar K, Dalakas MC. Inclusion body myositis and myopathies. Curr Opin Neurol. 1997;10:413.PubMedGoogle Scholar
  90. 90.
    Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol. 2007;6:620–31.PubMedGoogle Scholar
  91. 91.
    Badrising UA, Maat-Schieman MLC, van Houwelingen JC, van Doorn PA, van Duinen SG, van Engelen BGM, et al. Inclusion body myositis. Clinical features and clinical course in 64 patients. J Neurol. 2005;252:1448–54.PubMedGoogle Scholar
  92. 92.
    Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain. 1989;112:727.PubMedGoogle Scholar
  93. 93.
    Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol. 1992;19:1385.PubMedGoogle Scholar
  94. 94.
    Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine. 1991;70:360.PubMedGoogle Scholar
  95. 95.
    Cherin P. Treatment of inclusion body myositis. Curr Opin Rheum. 1999;11:456.Google Scholar
  96. 96.
    Tawil R, Griggs RC. Inclusion body myositis. Curr Opin Rheumatol. 2002;14:653–7.PubMedGoogle Scholar
  97. 97.
    Spector SA, Lemmer JT, Koffman BM, et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve. 1997;20:1242.PubMedGoogle Scholar
  98. 98.
    Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology. 1995;45:1302.PubMedGoogle Scholar
  99. 99.
    Calabrese LH, Mitsumoto H, Chou SM. Inclusion body myositis presenting as treatment-resistant polymyositis. Arthritis Rheum. 1987;30:397.PubMedGoogle Scholar
  100. 100.
    Cohen MR, Sulaiman AR, Grancis JC, et al. Clinical heterogeneity and treatment response in inclusion body myositis. Arthritis Rheum. 1989;32:734.PubMedGoogle Scholar
  101. 101.
    Leff RL, Miller FW, Hicks J, et al. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine. 1993;72:225.PubMedGoogle Scholar
  102. 102.
    Greenberg SA. How citation distortions create unfounded authority: analysis of a citation network. BMJ. 2009;339:b2680.PubMedGoogle Scholar
  103. 103.
    Salajegheh M, Pinkus JL, Nazareno R, Amato AA, Parker KC, Greenberg SA. Nature of “tau” immunoreactivity in normal myonuclei and inclusion body myositis. Muscle Nerve. 2009;40:520–8.PubMedGoogle Scholar
  104. 104.
    Greenberg SA. Theories of the pathogenesis of inclusion body myositis. Curr Rheumatol Rep. 2010;12:221–8.PubMedGoogle Scholar
  105. 105.
    Parker KC, Kong SW, Walsh RJ, Salajegheh M, Moghadaszadeh B, Amato AA, et al. Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis. Muscle Nerve. 2009;39:739–53.PubMedGoogle Scholar
  106. 106.
    Bohan A, Peter JB. Polymyositis and dermatomyositis (parts 1 and 2). N Engl J Med. 1975;292:344–403.PubMedGoogle Scholar
  107. 107.
    Bohan A, Peter JB, Bowman RL, et al. A computer-assited analysis of 153 patients with polymyositis and dermatomyositis. Medicine. 1977;56:255.PubMedGoogle Scholar
  108. 108.
    Baer AN. Differential diagnosis of idiopathic inflammatory myopathies. Curr Rheumatol Rep. 2006;8:178–87.PubMedGoogle Scholar
  109. 109.
    Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971–82.PubMedGoogle Scholar
  110. 110.
    Greenberg SA. Type 1 interferons and myositis. Arth Res Ther. 2010;12 Suppl 1:S4.Google Scholar
  111. 111.
    Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology. 2009;48:607–12.PubMedGoogle Scholar
  112. 112.
    Medsger TA, Dawson WN, Masi AT. The epidemiology of polymyositis. Am J Med. 1970;48:715.PubMedGoogle Scholar
  113. 113.
    Oddis CV, Conte CG, Steen VD, et al. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963–1982. J Rheumatol. 1990;17:1329.PubMedGoogle Scholar
  114. 114.
    Hochberg MC, Lopez-Acuna D, Gittelsohn AM. Mortality from polymyositis and dermatomyositis in the United States, 1968–1978. Arthritis Rheum. 1983;26:1465.PubMedGoogle Scholar
  115. 115.
    Lilley H, Dennett X, Byrne E. Biopsy proven polymyositis in Victoria 1982–1987: analysis of prognostic factors. J R Soc Med. 1994;87:323.PubMedGoogle Scholar
  116. 116.
    McKendry RJ. Influence of age at onset on the duration of treatment in idiopathic adult polymyositis and dermatomyositis. Arch Intern Med. 1987;147:1989.PubMedGoogle Scholar
  117. 117.
    Baron M, Small P. Polymyositis/dermatomyositis: clinical features and outcome in 22 patients. J Rheumatol. 1985;12:283.PubMedGoogle Scholar
  118. 118.
    Benbassat J, Gefel D, Larholt K, et al. Prognostic factors in polymyositis/dermatomyositis. Arthritis Rheum. 1985;28:249.PubMedGoogle Scholar
  119. 119.
    Callen JP. Relationship of cancer to inflammatory muscle diseases. Dermatomyositis, polymyositis and inclusion body myositis. Rheum Dis Clin North Am. 1994;20:943.PubMedGoogle Scholar
  120. 120.
    Koh ET, Seow A, Ong B, et al. Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis. 1993;52:857.PubMedGoogle Scholar
  121. 121.
    Lakhanpal S, Bunch TW, Ilstrup DM, et al. Polymyositis-dermatomyositis and malignant lesions: does an association exist? Mayo Clin Proc. 1986;61:645.PubMedGoogle Scholar
  122. 122.
    Rose AL, Walton JN. Polymyositis: a survey of 89 cases with particular reference to treatment and prognosis. Brain. 1966;89:747.PubMedGoogle Scholar
  123. 123.
    Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol. 1994;21:1855.PubMedGoogle Scholar
  124. 124.
    Emery AEH. The muscular dystrophies. Lancet. 2002;359:687–95.PubMedGoogle Scholar
  125. 125.
    Boonen S. Late onset muscular dystrophy. Proximal myopathy and recurrent falls in the elderly. Clin Rheumatol. 1995;14:586.PubMedGoogle Scholar
  126. 126.
    Abu-Baker A, Rouleau GA. Oculopharyngeal muscular ­dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies. Biochim Biophys Acta. 2007;1772:173–85.PubMedGoogle Scholar
  127. 127.
    Dalakas MC, Illa I, Pezeshkpour GH, et al. (1990): Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med. 1990;322:1098.PubMedGoogle Scholar
  128. 128.
    Yamamoto M, Koga Y, Ohtaki E, et al. Focal cytochrome c oxidase deficiency in various neuromuscular diseases. J Neurol Sci. 1989;91:207.PubMedGoogle Scholar
  129. 129.
    Johnston W, Karpati G, Carpenter S, et al. Late-onset mitochondrial myopathy. Ann Neurol. 1995;37:16.PubMedGoogle Scholar
  130. 130.
    Mendell JR. Mitochondrial myopathy in the elderly: exaggerated aging in the pathogenesis of disease. Ann Neurol. 1995;37:3.PubMedGoogle Scholar
  131. 131.
    Kastrup A, Gdynia H-J, Nagele T, Riecker A. Dropped-head syndrome due to steroid responsive focal myositis: a case report and review of the literature. J Neurol Sci. 2008;267:162–5.PubMedGoogle Scholar
  132. 132.
    Lenoir T, Guedj N, Boulu P, Guigui P, Benoist, Eur Spine J. 2010; epub DOI  10.1007/s00586–010–1370–5.
  133. 133.
    Petheram TG, Hourigan PG, Emran IM, Weatherly CR. Dropped head syndrome. A case series and literature review. Spine. 2008;33:47–51.PubMedGoogle Scholar
  134. 134.
    Karbowski K. The old and the new camptocormia. Spine. 1999;24:1494.PubMedGoogle Scholar
  135. 135.
    Laroche M, Delisle MB, Aziza R, et al. Is camptocormia a primary muscular disease? Spine. 1995;20:1011.PubMedGoogle Scholar
  136. 136.
    de Seze M-P, Creuze A, de Seze M, Mazaux. An orthosis and physiotherapy programme for camptocormia: a prospective case study. J Rehabil Med. 2008;40:761–765.Google Scholar
  137. 137.
    Biran I, Cohen O, Diment J, et al. Focal, steroid responsive myositis causing dropped head syndrome. Muscle Nerve. 1999;22:769.PubMedGoogle Scholar
  138. 138.
    Oerlemans WGH, de Visser M. Dropped head syndrome and bent spine syndrome: two separate clinical entities or different manifestations of axial myopathy. J Neurol Neurosurg Psychiatry. 1998;65:258.PubMedGoogle Scholar
  139. 139.
    Bagchi N, Brown TR, Parish RF. Thyroid dysfunction in adults over age 55 years. A study in an urban US community. Arch Intern Med. 1990;150:785.PubMedGoogle Scholar
  140. 140.
    Davis PJ, Davis FB. Hyperthyroidism in patients over the age of 60 years Clinical features in 85 patients. Medicine. 1974;53:161.PubMedGoogle Scholar
  141. 141.
    Doucet J, Trivalle C, Chassagne P, et al. Does age play a role in clinical presentation of hypothyroidism? J Am Geriatr Soc. 1994;42:984.PubMedGoogle Scholar
  142. 142.
    Trivalle C, Doucet J, Chassagne P, et al. Differences in the signs and symptoms of hyperthyroidism in older and younger patients. J Am Geriatr Soc. 1996;44:50.PubMedGoogle Scholar
  143. 143.
    Mastaglia FL, Ojeda VJ, Sarnat HB, et al. Myopathies associated with hypothyroidism: a review based upon 13 cases. Aust NZ J Med. 1988;18:799.Google Scholar
  144. 144.
    Rodolico C, Toscano A, Benvenga S, et al. Myopathy as the persistently isolated symptomatology of primary autoimmune hypothyroidism. Thyroid. 1998;8:1033.PubMedGoogle Scholar
  145. 145.
    Halverson PB, Kozin F, Ryan LM, et al. Rhabdomyolysis and renal failure in hypothyroidism. Ann Intern Med. 1975;91:57.Google Scholar
  146. 146.
    Torres CF, Moxley RT. Hypothyroid neuropathy and myopathy: clinical and electrodiagnostic longitudinal findings. J Neurol. 1990;237:271.PubMedGoogle Scholar
  147. 147.
    Golding DN. Rheumatism and the thyroid. J R Soc Med. 1993;86:130.PubMedGoogle Scholar
  148. 148.
    Hochberg MC, Koppes GM, Edwards CQ, et al. Hypothyroidism presenting as a polymyositis-like syndrome. Arthritis Rheum. 1976;19:1353.Google Scholar
  149. 149.
    Havard CWH. The thyroid and ageing. Clin Endocrinol Metab. 1981;10:163.Google Scholar
  150. 150.
    Reginato AJ, Falasca GF, Pappu R, et al. Musculoskeletal manifestations of osteomalacia: report of 26 cases and literature review. Semin Arthritis Rheum. 1999;28:287.PubMedGoogle Scholar
  151. 151.
    Jennekens FGI, Wokke JHJ. Proximal weakness of the extremities as main feature of amyloid myopathy. J Neurol Neurosurg Psych. 1987;50:1353.Google Scholar
  152. 152.
    Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc. 1983;58:665.PubMedGoogle Scholar
  153. 153.
    Dalakas MC. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry. 2009;80:832–8.PubMedGoogle Scholar
  154. 154.
    Askari A, Vignos PJ, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med. 1976;61:485.PubMedGoogle Scholar
  155. 155.
    Batchelor TT, Taylor LP, Thaler HT, et al. Steroid myopathy in cancer patients. Neurology. 1997;48:1234.PubMedGoogle Scholar
  156. 156.
    Schakman O, Gilson H, Kalista S, Thissen JP. Mechanisms of muscle atrophy by glucocorticoids. Horm Res. 2009;72 Suppl 1:36–41.PubMedGoogle Scholar
  157. 157.
    Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-protease pathway. N Engl J Med. 1996;335:1897.PubMedGoogle Scholar
  158. 158.
    Nury D, Doucet C, Coux O. Roles and potential therapeutic targets of the ubiquitin proteasome system in muscle wasting. BMC Biochem. 2007;8 Suppl 1:S7.PubMedGoogle Scholar
  159. 159.
    Merrick EL, Horgan CM, Hodgkin D, Garnick DW, Houghton SF, Panas L, et al. Unhealthy drinking patterns in older adults: prevalence and associated characteristics. J Am Geriatr Soc. 2008;56:214–23.PubMedGoogle Scholar
  160. 160.
    Al-Jarallah KF, Shebab DK, Buchanan WW. Rheumatic complications of alcohol abuse. Semin Arthritis Rheum. 1992;22:162.PubMedGoogle Scholar
  161. 161.
    Younger DS, Mayer SA, Weimer LH, et al. Colchicine-induced myopathy and neuropathy. Neurology. 1991;41:943.PubMedGoogle Scholar
  162. 162.
    Wallace SL, Singer JZ, Duncan GJ, et al. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol. 1991;18:264.PubMedGoogle Scholar
  163. 163.
    Pascuzzi RM. Drugs and toxins associated with myopathies. Curr Opin Rheum. 1998;10:511.Google Scholar
  164. 164.
    Gaist D, Rodríguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology. 2001;12:565–9.PubMedGoogle Scholar
  165. 165.
    Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlidemic patients- the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–14.PubMedGoogle Scholar
  166. 166.
    Tomlinson SS, Mangione KK. Potential adverse effects of statins on muscle. Phys Ther. 2005;85:459–65.PubMedGoogle Scholar
  167. 167.
    Rosenson RS. Current overview of statin-induced myopathy. Am J Med. 2004;116:408–16.PubMedGoogle Scholar
  168. 168.
    Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150:858–68.PubMedGoogle Scholar
  169. 169.
    Baker SK, Vladutiu GD, Peltier WL, Isackson PJ, Tarnopolsky MA. Metabolic myopathies discovered during investigations of statin myopathy. Can J Neurol Sci. 2008;35:94–7.PubMedGoogle Scholar
  170. 170.
    Venero CV, Thompson PD. Managing statin myopathy. Endocrinol Metab Clin N Am. 2009;38:121–36.Google Scholar
  171. 171.
    Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol. 2006;291:C1208–12.PubMedGoogle Scholar
  172. 172.
    Hanai J-I, Cao P, Tanksale P, Imamura S, Koshimizu E, Zhao J, et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest. 2007;117:3940–51.PubMedGoogle Scholar
  173. 173.
    Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy. J Am Coll Cardiol. 2007;49:2231–7.PubMedGoogle Scholar
  174. 174.
    SEARCH Collaborative Group. SLC01B1variants and statin-induced myopathy- a genomewide study. N Engl J Med. 2008;359:789–99.Google Scholar
  175. 175.
    Vaklavas C, Chatzizisis YS, Ziakis A, Zamboulis C, Giannoglou GD. Molecular basis of statin-associated myopathy. Atherosclerosis. 2009;202:18–28.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Medical Center BlvdWake Forest University School of MedicineWinston-SalemUSA

Personalised recommendations